Skip to search formSkip to main contentSkip to account menu

poziotinib

An orally bioavailable, quinazoline-based, mall-molecular and irreversible pan-epidermal growth factor receptor (EGFR or HER) inhibitor with… 
National Institutes of Health

Related topics

Related topics

3 relations
NCIt Antineoplastic Agent TerminologyReceptor Tyrosine Kinase Inhibition

Narrower (1)

NOV120101

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Abstract OT2-07-04: A phase 1b study of poziotinib in combination with T-DM1 in women with advanced or metastatic HER2-positive breast cancer
Background:Poziotinib represents a new class of irreversible quinazoline inhibitors of ErbB receptor tyrosine kinases that… 
2019
2019
Metastatic Breast Cancer Patient With Activating HER2 Exon 20 Insertion Mutation With Response to Poziotinib: Case Report of Compassionate Drug Use
2018
2018
A phase 2 study of poziotinib in patients with EGFR or HER2 exon 20 mutation-positive non-small cell lung cancer.
TPS9106Background: Poziotinib is a novel, oral, quinazoline-based pan-HER inhibitor that irreversibly blocks signaling through… 
2018
2018
Role of HER2 copy number amplification and PI3K pathway as a biomarker for patients with HER2+ MBC treating with Poziotinib, pan-HER TKI.
e13009Background: A phase II clinical trial of poziotinib, a pan- human epidermal growth factor receptor(HER) kinase inhibitor… 
2018
2018
Abstract 4772: Poziotinib overcomes de novo resistance of HER2 exon 20 mutations in NSCLC and other cancers: Preclinical studies and initial clinical testing
HER2 is mutated in ~3% of NSCLC cases, with most of these mutations occurring within exon 20. HER2 TKIs including afatinib and… 
2018
2018
Poziotinib Shows Promise for Rare Lung Cancer.
Poziotinib, an EGFR inhibitor that was previously shelved as ineffective against non-small cell lung cancer, is showing promising… 
2018
2018
Poziotinib for uncommon ERBB mutations
2017
2017
Abstract OT1-02-10: A phase 2 study of poziotinib in patients with HER2-positive metastatic breast cancer (MBC) who have received prior HER2 regimens for MBC
Background: Poziotinib is a novel, oral, quinazoline-based pan-HER inhibitor that irreversibly blocks signaling through the… 
2016
2016
Abstract OT3-01-10: A prospective, open-label, single-arm, multi-center, phase II exploratory study to evaluate the efficacy and safety of poziotinib (NOV120101) in patients with HER2-positive…
Background: Poziotinib is a novel, oral, irreversible pan-HER inhibitor that has shown promising clinical activity in Phase 1… 
2014
2014
Population pharmacokinetics of HM781-36 (poziotinib), pan-human EGF receptor (HER) inhibitor, and its two metabolites in patients with advanced solid malignancies
PurposeTo develop a population pharmacokinetic (PK) model for HM781-36 (poziotinib) and its metabolites in cancer patients… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)